iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
• Led by new investor Syncona, with participation from the…
Independent Cradle-to-Gate life cycle assessment shows AMSilk’s fibers have a significantly lower environmental footprint compared to silk
Neuried, Germany, 20 June 2024: AMSilk GmbH (“AMSilk”), a…
Gareth Williams appointed CEO of Bionical Health
Willington, UK, June 19, 2024 – Bionical Solutions, a leading…
Calliditas provides setanaxib patent update
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
AMSilk attends Pitti Filati for the first time to showcase biofabricated premium yarns
Neuried, Germany, 18 June 2024: AMSilk GmbH (“AMSilk”), a…
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled…
Resolution Therapeutics to Host Virtual Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.
Highlighting Clinical Data and Discovery Platform Following Presentations…
Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit
aXess is a restorative arteriovenous dialysis conduit which…
Climate resilient crops: Novo Nordisk Foundation and the Wellcome Trust award a grant of up to DKK 585 million to the ‘Ancient Environmental Genomics Initiative for Sustainability’
Harnessing environmental DNA, a new pioneering research project…
Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix® Spinal System
The Hague, Netherlands, 11 June 2024: Amber Implants (‘Amber’…
Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics
Commit Biologics is pioneering a novel approach to activating…
Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple…
Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation
Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab),…
Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024
VTX-801 increased ceruloplasmin ferroxidase activity and improved…
Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024
MATCH Phase 2 data underscores significant potential of macrophage…
New innovative crops could significantly reduce agriculture’s climate change impact and environmental footprint
The Novo Nordisk Foundation has awarded a grant of up to USD…
STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
STC-15 was well tolerated and clinical activity was observed…
Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia
Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper”…
Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”),…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York